1. Home
  2. CFLT vs NUVL Comparison

CFLT vs NUVL Comparison

Compare CFLT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Confluent Inc.

CFLT

Confluent Inc.

HOLD

Current Price

$30.66

Market Cap

7.7B

Sector

Technology

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$102.15

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFLT
NUVL
Founded
2014
2017
Country
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
8.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CFLT
NUVL
Price
$30.66
$102.15
Analyst Decision
Buy
Strong Buy
Analyst Count
29
15
Target Price
$29.13
$135.00
AVG Volume (30 Days)
18.8M
504.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.28
N/A
Revenue Next Year
$16.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.64
$55.54
52 Week High
$35.76
$113.02

Technical Indicators

Market Signals
Indicator
CFLT
NUVL
Relative Strength Index (RSI) 69.01 47.74
Support Level $30.49 $98.50
Resistance Level $30.60 $106.57
Average True Range (ATR) 0.12 4.92
MACD -0.08 -0.38
Stochastic Oscillator 98.72 35.93

Price Performance

Historical Comparison
CFLT
NUVL

About CFLT Confluent Inc.

Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: